Home > Insider Trading > Filing (0001209191-23-028884)

Filing Details

Accession Number:: 0001209191-23-028884
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-11 21:13:53
Reporting Period:: 2023-05-09

Accepted Time:: 2023-05-11 21:13:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1962918	Acelyrin Inc.	SLRN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1184592	C Beth Seidenberg	C/O Acelyrin, Inc. 4149 Liberty Canyon Rd. Agoura Hills CA 91301		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-09	8,540,729	$0.00	8,540,729	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2023-05-09	1,250,000	$18.00	9,790,729	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2023-05-09	60,000	$18.00	60,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Redeemable Convertible Preferred Stock	Disposition	2023-05-09	4,056,795	$0.00	4,056,795	$0.00
Common Stock	Series B Redeemable Convertible Preferred Stock	Disposition	2023-05-09	2,445,786	$0.00	2,445,786	$0.00
Common Stock	Series C Redeemable Convertible Preferred Stock	Disposition	2023-05-09	2,038,148	$0.00	2,038,148	$0.00
Class A Common Stock	Director Stock Option (right to buy)	Disposition	2023-05-09	23,243	$0.00	23,243	$18.00
Common Stock	Director Stock Option (right to buy)	Acquisiton	2023-05-09	23,243	$0.00	23,243	$18.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0	2033-05-03	No	4	J	Direct
23,243	2033-05-03	No	4	J	Direct

Footnotes

Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
Represents shares of Common Stock purchased through a directed share program in the IPO.
Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.